Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus

Usefulness of Empagliflozin Versus Liraglutide for Prevention of Cardiovascular Mortality

(2018) Ronen Arbel et al.   AMERICAN JOURNAL OF CARDIOLOGY

SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management

(2018) Michaël J.B. van Baar et al.   DIABETES CARE

HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING

(2018) Carol H. Wysham et al.   Endocrine Practice

Acute renal outcomes with SGLT-2 inhibitors - real world data analysis

(2018) Avivit Cahn et al.   DIABETES OBESITY & METABOLISM

Incidence and risk of vaginal candidiasis associated with SGLT2 inhibitors in real-world practice for women with type 2 diabetes

(2018) Hiroki Yokoyama et al.   Journal of Diabetes Investigation

Body Weight Considerations in the Management of Type 2 Diabetes

(2018) Caroline M. Apovian et al.   ADVANCES IN THERAPY

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

(2017) Bruce Neal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Liraglutide and Renal Outcomes in Type 2 Diabetes

(2017) Johannes F.E. Mann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effectiveness of long-term treatment with SGLT2 inhibitors: real-world evidence from a specialized diabetes center

(2017) Yotsapon Thewjitcharoen et al.   Diabetology & Metabolic Syndrome

Effect of Sodium‐Glucose Cotransport‐2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis of 43 Randomized Control Trials With 22 528 Patients

(2017) Mohsen Mazidi et al.   Journal of the American Heart Association

Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus

(2016) Hiddo J.L. Heerspink et al.   CIRCULATION

SGLT2 Inhibitors and the Diabetic Kidney

(2016) Paola Fioretto et al.   DIABETES CARE

Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials

(2016) Dandan Li et al.   DIABETES OBESITY & METABOLISM

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial

(2016) David Fitchett et al.   EUROPEAN HEART JOURNAL

Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus

(2016) Curt J. Carlson et al.   Expert Opinion On Drug Safety

Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants

(2016)   LANCET

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

(2016)   NEW ENGLAND JOURNAL OF MEDICINE

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

(2016) Christoph Wanner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials

(2016) Kristina Johnsson et al.   POSTGRADUATE MEDICINE

Sodium–glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy

(2015) Marko Škrtić et al.   CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION

Add-On Treatment with Liraglutide Improves Glycemic Control in Patients with Type 2 Diabetes on Metformin Therapy

(2015) Eusebio Chiefari et al.   Diabetes Technology & Therapeutics

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genetics, Ancestry, and Hypertension: Implications for Targeted Antihypertensive Therapies

(2014) Nora Franceschini et al.   CURRENT HYPERTENSION REPORTS

Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies

(2014) Paul Nyirjesy et al.   CURRENT MEDICAL RESEARCH AND OPINION

Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin

(2014) M. A. Nauck et al.   DIABETES OBESITY & METABOLISM

Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus

(2014) André J. Scheen   DRUGS

Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis

(2014) William L. Baker et al.   Journal of the American Society of Hypertension

Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes

(2013) Despoina Vasilakou et al.   ANNALS OF INTERNAL MEDICINE

Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials

(2013) M. Monami et al.   DIABETES OBESITY & METABOLISM

Achievement of Goals in U.S. Diabetes Care, 1999–2010

(2013) Mohammed K. Ali et al.   NEW ENGLAND JOURNAL OF MEDICINE

A polymorphism of HMGA1 is associated with increased risk of metabolic syndrome and related components

(2013) Eusebio Chiefari et al.   Scientific Reports

Long-term Renal Outcomes of Patients With Type 1 Diabetes Mellitus and MicroalbuminuriaAn Analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications CohortMicroalbuminuria Outcomes in Type 1 Diabetes

(2011) Ian H. de Boer   ARCHIVES OF INTERNAL MEDICINE

A New Approach to Glucose Control in Type 2 Diabetes: The Role of Kidney Sodium-Glucose Co-transporter 2 Inhibition

(2011) Jan Basile   POSTGRADUATE MEDICINE